WFA Asset Management’s AstraZeneca AZN Stock Holding History

WFA Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13	Closed	-$1.69K	–	229
2023 Q3	$1.69K	Buy	+13	New	+$1.78K	﹤0.01%	224

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

WFA Asset Management's AZN Position: Q4 2023 in Review

WFA Asset Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 13 shares — an estimated $1.69K sold.

WFA Asset Management first reported a position in AZN in Q3 2023 and held it in 1 quarter. The position peaked at $1.69K in Q3 2023. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

WFA Asset Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
WFA Asset Management sold 13 AstraZeneca shares in Q4 2023, an estimated $1.69K.
WFA Asset Management first reported a position in AstraZeneca in Q3 2023 and held it in 1 quarter.
WFA Asset Management's AstraZeneca position peaked at $1.69K in Q3 2023.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on WFA Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.